Format

Send to

Choose Destination
J Hepatol. 2008 Aug;49(2):295-8. doi: 10.1016/j.jhep.2008.03.033. Epub 2008 May 22.

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.

Author information

1
Division of Clinical Pathology, University Hospital, 24 rue Micheli-du-Crest, 1211 Geneva 4, Switzerland.

Abstract

BACKGROUND/AIMS:

Insulin resistance reduces the response to interferon alfa-based therapy of chronic hepatitis C patients. It has been speculated that improvement of insulin sensitivity might increase the chances of responding to treatment of such individuals.

METHODS:

We started a multicenter clinical trial of retreatment of chronic hepatitis C patients, who had failed to respond to the pegylated interferon alfa/ribavirin combination, with a triple therapy consisting in these same antivirals plus an insulin-sensitizer (pioglitazone) (The INSPIRED-HCV study).

RESULTS:

None of the first five patients fulfilling the inclusion criteria and included in the trial achieved a satisfactory virological response after 12 weeks of retreatment, despite the fact that in at least three of them the insulin resistance score improved. As a result, the study was terminated.

CONCLUSIONS:

Different schedules are warranted to improve insulin sensitivity prior to attempting retreatment of chronic hepatitis C patients with insulin resistance.

PMID:
18555553
DOI:
10.1016/j.jhep.2008.03.033
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center